|

Apalutamide (Erleada™) 60 mg or 240 mg tablets Clinical Trials

3 actively recruiting trials across 1 location

▲ +1 trial since June 2026

Pipeline

Phase 1: 1Phase 3: 1

Top Sponsors

  • ORIC Pharmaceuticals1
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS1
  • Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD1

Indications

  • Cancer3
  • Metastatic Hormone-sensitive Prostate Cancer1
  • Castrate Sensitive Prostate Cancer1
  • Metastatic Prostate Cancer1
  • Metastatic Cancer1

Other2 trials

PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer
Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.
Phase 3

Colorado Springs, Colorado1 trial

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

Rocky Mountain Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.